Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Servier Group Partners with n-Lorem Foundation to Develop ASO Therapies for Rare Neurodevelopmental Disorders

Fineline Cube Jun 17, 2026
Company Deals

Shanghai Juncell Therapeutics Files for HKEX Listing with Breakthrough TIL Therapy GC101 for Solid Tumors

Fineline Cube Jun 17, 2026
Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Fineline Cube Jun 16, 2026
Company Deals

Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets

Fineline Cube Jun 16, 2026
Company Deals

AstraZeneca Joins ZERO Prostate Cancer’s Blitz the Barriers Initiative – Ambitious Program Aims to Save 100,000 Lives by 2035

Fineline Cube Jun 16, 2026
Policy / Regulatory

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

Fineline Cube Jun 17, 2026
Company Drug

Hengrui Pharmaceuticals Receives NMPA Clinical Approvals for Two Novel Anti-Tumor Candidates SHR-6914 and HRS-7525, Addressing Unmet Needs in Prostate Cancer and Solid Tumors

Fineline Cube Jun 17, 2026
Company Drug

Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan Receives EMA Orphan Drug Designation for Pulmonary Neuroendocrine Carcinomas

Fineline Cube Jun 17, 2026
Company Deals

CORXEL Secures Licensing Rights for Biogen’s BIIB131 in Stroke Treatment

Fineline Cube Jan 12, 2024

Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, supported by RTW Investments, has secured a...

Company

Boehringer Ingelheim Expands Greek Facility to Boost Production of Jardiance and Other Medications

Fineline Cube Jan 12, 2024

Boehringer Ingelheim (BI), headquartered in Germany, has commenced the expansion of its manufacturing facility in...

Company

Fosun Kite and Medi Cover Launch First Value-Based Payment Plan for Lymphoma Treatment

Fineline Cube Jan 12, 2024

Fosun Kite and Medi Cover, a health management and patient service platform under Sinopharm (HKG:...

Company Drug

Novo Nordisk’s IcoSema Shows Promise in Late-Stage Trial for Type 2 Diabetes Management

Fineline Cube Jan 12, 2024

Danish pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has announced positive results from a late-stage trial...

Company Drug

AbbVie’s Lutikizumab Advances to Phase III for Hidradenitis Suppurativa After Positive Mid-Stage Results

Fineline Cube Jan 12, 2024

AbbVie (NYSE: ABBV) has announced the progression of lutikizumab to Phase III clinical trials following...

Company

Changchun High & New Technology to Transfer 7.42% Stake to Ex-Wife in Divorce Settlement

Fineline Cube Jan 12, 2024

Changchun High & New Technology Industries (Group) Inc., (SHE: 000661) has announced plans to transfer...

Company Drug

Bio-Thera Solutions Receives NMPA Approval for Combined Phase Ib/II Study of BAT7104 and BAT4706

Fineline Cube Jan 12, 2024

Bio-Thera Solutions Ltd (SHA: 688177), a Chinese biopharmaceutical company, has announced that it has received...

Company Drug

Eisai’s Lemborexant Sleep Aid Lemborexant Filed for NMPA Approval in China

Fineline Cube Jan 12, 2024

The China Center for Drug Evaluation (CDE) website has indicated that Japan-based Eisai (TYO: 4523)...

Company

Astellas Pharma Appoints Zhao Ping as Chairman of China Operations

Fineline Cube Jan 12, 2024

Effective January 15, 2024, Astellas Pharma (TYO: 4503), a leading Japanese pharmaceutical company, has appointed...

Company Deals

Keylights Biotechnology Raises $14 Million in Series B to Expand IVD Instrument Range

Fineline Cube Jan 12, 2024

Keylights Biotechnology Co., Ltd., a leading in vitro diagnostic (IVD) instruments manufacturer headquartered in Shenzhen,...

Company Drug

Joincare Pharmaceutical’s Partner Fermion Gets NMPA Green Light for Pain Drug Clinical Study

Fineline Cube Jan 12, 2024

Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has announced that...

Company Deals

Gansu Deshengtang Partners with RELEX Solutions to Enhance Supply Chain Efficiency

Fineline Cube Jan 12, 2024

Gansu Deshengtang Medical Science and Technology Group Co., Ltd, a prominent Chinese healthcare group, has...

Company Drug

GSK Secures Second Indication Approval for Nucala in China for Severe Eosinophilic Asthma

Fineline Cube Jan 11, 2024

GSK plc (NYSE: GSK) has received approval for a second indication in China for its...

Company Deals

China Resources Medical Laboratory Partners with Qlife Lab for Comprehensive Mass Spectrometry Solutions

Fineline Cube Jan 11, 2024

China Resources Medical Holdings Company Limited’s subsidiary, China Resources (Guangdong) Medical Laboratory Co., Ltd, has...

Company Deals

WuXi Biologics Partners with BioNTech to Develop Next-Gen Antibodies in $20 Million Deal

Fineline Cube Jan 11, 2024

WuXi Biologics (HKG: 2269), a China-based Contract Research, Development, and Manufacturing Organization (CRDMO), has entered...

Company Deals

Junshi Biosciences Regains Global Rights to JS006 as Coherus Terminates Licensing Agreement

Fineline Cube Jan 11, 2024

Junshi Biosciences (HKG: 1877; SHA: 688180), based in Suzhou, has announced the termination of its...

Policy / Regulatory

China’s NHC Unveils Strategy to Enhance Pediatric Healthcare by 2025

Fineline Cube Jan 11, 2024

The National Health Commission (NHC) has issued a set of Opinions aimed at “Promoting the...

Company Deals

Amgen Licenses XeriJect Technology from Xeris Biopharma for Subcutaneous Tepezza Development

Fineline Cube Jan 11, 2024

Amgen (NASDAQ: AMGN) has entered into a licensing agreement with Xeris Biopharma (NASDAQ: XERS) for...

Company Drug

Eli Lilly Secures NMPA Approval for Emgality as Preventive Migraine Treatment in China

Fineline Cube Jan 11, 2024

Eli Lilly (NYSE: LLY) has received marketing approval from the National Medical Products Administration (NMPA)...

Company

C4 Therapeutics Outlines 2024 Focus Amid 30% Workforce Reduction, Prioritizes Key Oncology Trials

Fineline Cube Jan 11, 2024

C4 Therapeutics (NASDAQ: CCCC), a leader in protein degradation, announced this week its strategic focus...

Posts pagination

1 … 435 436 437 … 685

Recent updates

  • Hengrui Pharmaceuticals Receives NMPA Clinical Approvals for Two Novel Anti-Tumor Candidates SHR-6914 and HRS-7525, Addressing Unmet Needs in Prostate Cancer and Solid Tumors
  • Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan Receives EMA Orphan Drug Designation for Pulmonary Neuroendocrine Carcinomas
  • Luye Pharma’s Dual-Target Candidate LY03015 Achieves Breakthrough Phase II Results in Tardive Dyskinesia with 76.5% Response Rate
  • GSK’s Momelotinib Receives Orphan Drug Designation from FDA and EMA for VEXAS Syndrome, Addressing Critical Unmet Need in Rare Myeloid Disorder
  • Regent Pacific’s Senstend Receives NMPA Approval with Four-Year Data Protection, Triggering $5M Milestone Payment from Wanbang
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Receives NMPA Clinical Approvals for Two Novel Anti-Tumor Candidates SHR-6914 and HRS-7525, Addressing Unmet Needs in Prostate Cancer and Solid Tumors

Company Drug

Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan Receives EMA Orphan Drug Designation for Pulmonary Neuroendocrine Carcinomas

Company Drug

Luye Pharma’s Dual-Target Candidate LY03015 Achieves Breakthrough Phase II Results in Tardive Dyskinesia with 76.5% Response Rate

Company Drug

GSK’s Momelotinib Receives Orphan Drug Designation from FDA and EMA for VEXAS Syndrome, Addressing Critical Unmet Need in Rare Myeloid Disorder

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.